A PHASE 1A/1B, OPEN-LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY OF EZN-4176, AN ANDROGEN RECEPTOR MRNA ANTAGONIST, IN ADULT PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER.

Trial Profile

A PHASE 1A/1B, OPEN-LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY OF EZN-4176, AN ANDROGEN RECEPTOR MRNA ANTAGONIST, IN ADULT PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Oct 2013

At a glance

  • Drugs EZN 4176 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man
  • Sponsors Enzon Pharmaceuticals
  • Most Recent Events

    • 17 Dec 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 12 Oct 2011 Actual initiation date (March 2011) added as reported by ClinicalTrials.gov.
    • 18 Apr 2011 New source identified and integrated (ClinicalTrials.gov).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top